|
Mental disorders
|
0.010 |
AlteredExpression
|
group |
BEFREE |
STriatal-Enriched protein tyrosine Phosphatase (STEP) is a neural-specific protein that opposes the development of synaptic strengthening and whose levels are altered in several neurodegenerative and psychiatric disorders.
|
30760987 |
2018 |
|
Abnormal behavior
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
STriatal-Enriched protein tyrosine Phosphatase (STEP) is a neural-specific protein that opposes the development of synaptic strengthening and whose levels are altered in several neurodegenerative and psychiatric disorders.
|
30760987 |
2018 |
|
Neuroblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
A<sub>2A</sub> Rs modulate STEP activity also in the SH-SY5Y neuroblastoma cell line, where a calcium-dependent calcineurin/PP1 pathway was found to play a major role.
|
31520531 |
2020 |
|
Central neuroblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
A<sub>2A</sub> Rs modulate STEP activity also in the SH-SY5Y neuroblastoma cell line, where a calcium-dependent calcineurin/PP1 pathway was found to play a major role.
|
31520531 |
2020 |
|
Childhood Neuroblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
A<sub>2A</sub> Rs modulate STEP activity also in the SH-SY5Y neuroblastoma cell line, where a calcium-dependent calcineurin/PP1 pathway was found to play a major role.
|
31520531 |
2020 |
|
Alzheimer's Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
Accumulating evidence over the past decade indicates that STEP dysregulation contributes to the pathophysiology of several neuropsychiatric disorders, including Alzheimer's disease, schizophrenia, fragile X syndrome, epileptogenesis, alcohol-induced memory loss, Huntington's disease, drug abuse, stroke/ischemia, and inflammatory pain.
|
22090472 |
2012 |
|
Amnesia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Accumulating evidence over the past decade indicates that STEP dysregulation contributes to the pathophysiology of several neuropsychiatric disorders, including Alzheimer's disease, schizophrenia, fragile X syndrome, epileptogenesis, alcohol-induced memory loss, Huntington's disease, drug abuse, stroke/ischemia, and inflammatory pain.
|
22090472 |
2012 |
|
Memory Loss
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Accumulating evidence over the past decade indicates that STEP dysregulation contributes to the pathophysiology of several neuropsychiatric disorders, including Alzheimer's disease, schizophrenia, fragile X syndrome, epileptogenesis, alcohol-induced memory loss, Huntington's disease, drug abuse, stroke/ischemia, and inflammatory pain.
|
22090472 |
2012 |
|
Inflammatory pain
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Accumulating evidence over the past decade indicates that STEP dysregulation contributes to the pathophysiology of several neuropsychiatric disorders, including Alzheimer's disease, schizophrenia, fragile X syndrome, epileptogenesis, alcohol-induced memory loss, Huntington's disease, drug abuse, stroke/ischemia, and inflammatory pain.
|
22090472 |
2012 |
|
Huntington Disease
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Alterations in STriatal-Enriched protein tyrosine Phosphatase expression, activation, and downstream signaling in early and late stages of the YAC128 Huntington's disease mouse model.
|
24588402 |
2014 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.010 |
Biomarker
|
disease |
BEFREE |
Artefactual inflation of type 2 diabetes prevalence in WHO STEP surveys.
|
30706604 |
2019 |
|
Mechanical Allodynia
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Behavioral tests showed that LTP blockade by STEP61(WT) correlated with a long-lasting alleviation of thermal hypersensitivity and mechanical allodynia induced by chronic constriction injury of sciatic nerves.
|
28389375 |
2017 |
|
Hypertensive disease
|
0.010 |
Biomarker
|
group |
BEFREE |
Burden of hypertension in The Gambia: evidence from a national World Health Organization (WHO) STEP survey.
|
29394353 |
2018 |
|
Mixed anxiety and depressive disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Child STEPs in California: A cluster randomized effectiveness trial comparing modular treatment with community implemented treatment for youth with anxiety, depression, conduct problems, or traumatic stress.
|
27548030 |
2017 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Correction to: Oncology practitioners' perspectives and practice patterns of post-treatment cancer survivorship care in the Asia-Pacific region: results from the STEP study.
|
29495960 |
2018 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
Correction to: Oncology practitioners' perspectives and practice patterns of post-treatment cancer survivorship care in the Asia-Pacific region: results from the STEP study.
|
29495960 |
2018 |
|
Myopia
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Detection and interpretation of shared genetic influences on 42 human traits.
|
27182965 |
2016 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Development and validation of simple step protein precipitation UHPLC-MS/MS methods for quantitation of temozolomide in cancer patient plasma samples.
|
30243056 |
2019 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
Development and validation of simple step protein precipitation UHPLC-MS/MS methods for quantitation of temozolomide in cancer patient plasma samples.
|
30243056 |
2019 |
|
Mental Depression
|
0.010 |
Biomarker
|
disease |
BEFREE |
Earlier we showed that striatal-enriched protein tyrosine phosphatase (STEP) inhibitor - 8-(trifluoromethyl)-1,2,3,4,5-benzopentathiepin-6-amine hydrochloride (TC-2153) affects both the brain serotoninergic system and the brain-derived neurotropic factor that are known to be involved in the psychopathology of depression.
|
30367948 |
2018 |
|
Depressive disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Earlier we showed that striatal-enriched protein tyrosine phosphatase (STEP) inhibitor - 8-(trifluoromethyl)-1,2,3,4,5-benzopentathiepin-6-amine hydrochloride (TC-2153) affects both the brain serotoninergic system and the brain-derived neurotropic factor that are known to be involved in the psychopathology of depression.
|
30367948 |
2018 |
|
Depressed mood
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Earlier we showed that striatal-enriched protein tyrosine phosphatase (STEP) inhibitor - 8-(trifluoromethyl)-1,2,3,4,5-benzopentathiepin-6-amine hydrochloride (TC-2153) affects both the brain serotoninergic system and the brain-derived neurotropic factor that are known to be involved in the psychopathology of depression.
|
30367948 |
2018 |
|
Alzheimer's Disease
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Excessive activity of striatal-enriched protein tyrosine phosphatase (STEP) in the brain has been detected in numerous neuropsychiatric disorders including Alzheimer's disease.
|
29116812 |
2017 |
|
Idiopathic Pulmonary Fibrosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Exploratory analyses of the STEP-IPF (Sildenafil Trial of Exercise Performance in IPF) trial suggested that sildenafil may have a greater effect on SGRQ score in patients with IPF who have right heart dysfunction (RHD).<b>Objectives:</b> Assess whether RHD influenced the effects of nintedanib plus sildenafil versus nintedanib alone in the INSTAGE trial.<b>Methods:</b> Subgroup analyses of patients with (<i>n</i> = 117) versus those without (<i>n</i> = 156) echocardiographic signs of RHD at baseline.<b>Measurements and Main Results:</b> There was no heterogeneity between subgroups by presence of RHD in the effect of nintedanib plus sildenafil versus nintedanib alone on change in SGRQ total score at Week 12 (<i>P</i> = 0.74) or Week 24 (<i>P</i> = 0.90), or change in FVC at Week 12 (<i>P</i> = 0.58) or Week 24 (<i>P</i> = 0.55).
|
31365829 |
2019 |
|
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
Further, PTPN5 expression is strongly associated with good clinical outcome in tamoxifen treated human breast cancer patients suggesting that PTPN5 may represent a novel biomarker of tamoxifen response in human breast cancer.
|
29590203 |
2018 |